We are sorry, the requested page does not exist
Jodi Sta. Maria tinamaan ng COVID kaya hindi nakarating sa party ni Mr. M
MAY balidong rason pala si Jodi Sta. Maria kaya hindi nakadalo sa “Night of 100 Stars” tribute para kay Johnny Manahan na kilala bilang Mr. M. Hindi raw totoo na binawi ang imbitasyon kay Jodi dahil mas pinaboran daw si Claudine Barretto sa event. Tinamaan daw ng COVID-19 si Jodi. Nasulat namin dito sa BANDERA ang.....»»
Medical, but hold the marijuana: new CBD source found in Brazil
In a laboratory tucked away on a sprawling university campus in Rio de Janeiro, Brazilian molecular biologist Rodrigo Moura Neto is running tests on a seemingly ordinary plant with a potent secret. The fast-growing, homely plant, Trema micrantha blume, is native to the Americas, where it is widespread and often considered a weed. But Moura Neto recently discovered its fruits and flowers contain one of the active ingredients in marijuana: cannabidiol, or CBD, which has shown promise as a treatment for conditions including epilepsy, autism, anxiety and chronic pain. Crucially, he also found it does not contain the other main ingredient in pot, tetrahydrocannabinol, or THC -- the psychoactive substance that makes people high. That opens the possibility of an abundant new source of CBD, without the complications of cannabis, which remains illegal in many places. The discovery has made something of an overnight academic star of Dr Moura Neto, an affable, silver-haired 66-year-old who now has a packed schedule of meetings with patent experts and companies keen to tap the multi-billion-dollar CBD market. "It was wonderful to find a plant (with CBD but) without THC, because you avoid all the mess around psychotropic substances," says Moura Neto, who has spent the better part of five decades researching in this small lab at Rio de Janeiro Federal University. "That means the potential is enormous," he tells AFP. His 10-member team recently won a 500,000-real ($104,000) public grant to expand his project, which will now identify the best methods to extract CBD from "Trema," then study its effectiveness as a substitute for medical marijuana. Man in demand Many of CBD's touted medical uses are still under research. The compound is controversial, including in Brazil, where patients have gone to court to win the right to use it. They often have to import it at eye-watering prices, given that cultivating medical marijuana remains illegal -- though there is legislation before Congress to change that. Debates aside, demand for CBD is booming. The global market for CBD last year was estimated at nearly $5 billion. Analytics firm Vantage Market Research projects it will grow to more than $47 billion by 2028, driven mainly by health and wellness use. Interest in Moura Neto's research has been "huge," says Rosane Silva, the director of his laboratory, which sits off a hallway bustling with students and researchers in white lab coats. "Lots of companies have been calling, looking to collaborate" on an eventual non-cannabis-based CBD medication, Silva says, standing beside what she calls the "magical plant." A member of the Cannabaceae family -- like cannabis -- "Trema" can grow into a tree up to 20 meters (66 feet) tall. Moura Neto says he and the university may explore patenting any innovations they find for extracting CBD from its tiny fruits and flowers. But he is quick to add he won't patent "Trema" itself. He wants scientists everywhere to be able to research it. "If I dreamed of being a billionaire, I wouldn't have become a professor," he says. From policing to producing? Moura Neto started studying CBD for a completely different reason: trained as a forensic geneticist, he would analyze the DNA of marijuana seized by police to help investigators trace its source. When he came across a study that identified CBD in a related plant in Thailand -- another member of the Cannabaceae family -- he got the idea to test for it in "Trema." He says turning his still-unpublished findings into a drug ready for market will take five to 10 years of research and clinical trials -- if it is possible at all. Cannabis, first domesticated in China more than 10,000 years ago, has been cultivated for millennia to hone its mind-altering and medicinal effects. CBD from "Trema" might not work as well, or at all, Moura Neto says. In the meantime, it's no use smoking the plant for a high. "That definitely won't do anything for you," he laughs. The post Medical, but hold the marijuana: new CBD source found in Brazil appeared first on Daily Tribune......»»
Rubbing vaginal fluid on C-section babies boosts development: study
Babies born by cesarean section don't acquire the same healthy bacteria as those delivered vaginally, a setback to the development of their immune system thought to increase their risk of certain diseases later in life. But a new study, published Thursday in the journal Cell Host & Microbe, finds that exposing C-section babies to their mother's vaginal fluids after birth successfully restores this microbial balance, and has neurodevelopment benefits, too. The study used rigorous methods but was small, involving just 68 infants. Coauthor Jose Clemente of the Icahn School of Medicine at Mount Sinai told AFP that if the findings are confirmed in bigger clinical trials, the technique could be used as a low-cost way to ensure C-section newborns start life on the same footing as vaginally delivered infants. "If the results can be generalizable to a larger population, then ideally we would like to see that this becomes a part of standard of care," he said. It comes as C-section rates are on the rise globally, now accounting for around one in every three births in the United States, though the World Health Organization estimates only 10-15 percent are medically necessary. Past research has shown infants born by C-section have vastly different gut bacteria composition compared to those born vaginally. The latter receive their early gut bacteria from their mother's birth canal, while C-section babies receive theirs mainly from their mothers' skin, breast milk and the environment. These differences tend to disappear by around the age of one, but even so, they can have certain lasting impacts, raising the risk for asthma, allergies and diabetes. 'Vaginal seeding' In the new study, Clemente, an expert on the role of the microbiome in human health, collaborated with colleagues at the Southern Medical University in Guangzhou, China to test out a technique known as "vaginal seeding," or smearing newborns with vaginal fluid. Chinese colleagues, led by researcher Yan He, rubbed 32 newborns delivered by C-section with a gauze soaked with their mother's vaginal fluids, and another 36 newborns with a gauze soaked with saline as a control. The gauze was placed inside the mothers' vaginas about an hour before C-section. Applying it to babies took about 30 seconds, starting with the mouth and face and moving to the rest of the body. Mothers were tested in advance to make sure they did not have sexually transmitted diseases or group B streptococcus. No infants experienced severe adverse events as a result of the experiment. At six-weeks-old, the group exposed to vaginal fluid had gut bacteria that was more "mature" and more characteristic of vaginally delivered babies than the group given the saline placebo. The team also looked at the babies' neurodevelopment at three months and six months using a standard questionnaire to ask their mothers about milestones, such as whether the babies were able to make simple sounds or had begun rolling or getting in the crawl position. The infants who received the vaginal seeding scored significantly higher at both three and six months. "We think this is partially because of how microbes are producing certain chemical compounds that might impact brain function," said Clemente, an expanding field of study that is backed by animal research. Crucially, he stressed, the experiment was "triple blinded," meaning nobody involved (mothers, healthcare providers or researchers) knew beforehand which babies belonged to which group, in order to eliminate any temptation to make the results match expectations. Dorothy Bishop, a developmental neuropsychology expert at the University of Oxford, who was not involved in the study, praised the "clever design," and said the team had laid the groundwork for bigger trials by establishing the safety and feasibility of the technique. However, she stressed that they had not yet proven developmental benefit and that the test scores from the placebo group "seem pretty average" rather than suggesting impairment. Next, Clemente is looking to expand the study with his Chinese collaborators to move the procedure closer to clinical practice, while he has another ongoing study assessing whether it reduces the risk of food allergies. In the meantime, he says, families should not try to replicate the procedure outside of clinical research settings. The post Rubbing vaginal fluid on C-section babies boosts development: study appeared first on Daily Tribune......»»
Vaccine czar Galvez kinontra ng FDA sa anunsiyo na pagtuturok ng Sinovac sa seniors
Naninindigan ang Food and Drug Administration (FDA) na hindi maaring iturok sa senior citizens ang Sinovac bilang proteksyon kontra Covid-19. Sinabi ni FDA Dir. Gen. Eric Domingo na malinaw sa emergency use authorization (EUA) ng gawang China na bakuna na maari lang itong ibigay sa mga may edad 18 hanggang 59. Dagdag pa niya, maituturok […] The post Vaccine czar Galvez kinontra ng FDA sa anunsiyo na pagtuturok ng Sinovac sa seniors appeared first on Bandera......»»
Tagalog News: Bakuna kontra COVID-19 dumating na sa OrMin
LUNGSOD NG CALAPAN, Oriental Mindoro, Mar. 5 (PIA) -- Dumating na sa Calapan Airport ang mga bakuna mula China, ang Sinovac Vaccine lulan ng Philippinw Coast Guard helicopter kanina.Dumating.....»»
Bakuna kasado na! Modernisasyon ng BFP umuusad sa Senado
Ikinalulugod natin ang umpisa ng linggong ito dahil nitong Lunes, unang araw ng Marso, ay opisyal nang sinimulan ang national vaccination program ng ating pamahalaan. Tumanggap ng kauna-unahang turok ng bakuna laban sa COVID-19 sa bansa si Philippine General Hospital Director Dr. Gerardo “Gap” Legaspi. Donasyon ng bansang China ang ginamit na bakunang Coronavac, gawa ng Chinese company na Sinovac Biotech. The post Bakuna kasado na! Modernisasyon ng BFP umuusad sa Senado first appeared on Abante......»»
Paggamit ng Sinovac vaccine sa health workers aprubado na ng IATF
Inaprubahan ng Inter-Agency Task Force (IATF) on Emerging Infectious Diseases ang rekomendasyon ng National Immunization Technical Advisory Group (NITAG) na gamitin ang bakuna kontra Covid-19 na gawa ng Sinovac ng China sa mga health workers kahit nasa 50.4 percent lamang ang efficacy rate nito. Ito ang inihayag ni Health Undersecretary Maria Rosario Vergeire sa virtual […] The post Paggamit ng Sinovac vaccine sa health workers aprubado na ng IATF appeared first on Bandera......»»
50K donasyong China vaccine mapupunta sa AFP
Inihayag ng Armed Forces of the Philippines (AFP) na kalahati mula sa 100,000 bakuna kontra COVID-19 na donasyon ng China sa bansa ay mapupunta sa mga sundalo. The post 50K donasyong China vaccine mapupunta sa AFP first appeared on Abante......»»
Belgian firm umpisa na clinical trial
Inihayag ng Department of Science and Technology (DOST) nitong Biyernes na nagsimula na sa kanilang clinical trial para sa bakuna kontra COVID-19 ang isang pharmaceutical company na nakabase sa Belgium. The post Belgian firm umpisa na clinical trial first appeared on Abante......»»
Sputnik V vaccine ng Russia, 91.6% effective vs COVID-19 – pag-aaral
MANILA, Philippines – Nakitaan ng 91.6 porsyentong epektibo ang bakuna ng Russia Sputnik V laban sa Coronavirus Disease 2019, ayon sa resulta ng pagsusuri na inilabas sa The Lancet, Martes. Ang Sputnik V – pinangalan sa Soviet-era satellite – ay inaprubahan ng Russia buwan bago isailalim ito sa pinakahuling stage ng clinical trials na nagresulta […] The post Sputnik V vaccine ng Russia, 91.6% effective vs COVID-19 – pag-aaral appeared first on REMATE ONLINE......»»
Sinovac cleared for COVID-19 vaccine clinical trials in the Philippines
China's Sinovac has secured approval to hold clinical trials in the country for its coronavirus vaccine, local regulators said Tuesday......»»
Vaccine exec vows transparency on test results
A senior executive of Sinovac, one of the makers of China’s leading vaccine candidates, said the firm would be transparent on the results of its clinical tests as it assured the Philippines it would provide “affordable” vaccines......»»
Sinovac vaccine ng China wala pang 60% na epektibo, ayon sa pag-aaral sa Brazil
SAO PAULO — Mababa pa sa 60 porsyento na epektibo ang vaccine ng Sinovac Biotech ng China, ayon sa late-stage trial na isinagawa sa Brazil. Nag-partner ang Butantan biomedical center ng Sao Paolo at ang Sinovac para pag-aralan ang bakuna ng China sa Brazil at nakatakdang ilabas ang resulta ng kanilang pagsusuri ngayong Martes. Noong […] The post Sinovac vaccine ng China wala pang 60% na epektibo, ayon sa pag-aaral sa Brazil appeared first on Bandera......»»
China’s Clover gets nod for Philippine trials
The Food and Drug Administration yesterday approved the application of Chinese firm Clover Biopharmaceuticals to conduct clinical trials in the Philippines for its COVID-19 vaccine......»»
DOST: Sinopharm wanted PH to fund local COVID-19 vaccine trial
Chinese firm Sinopharm had wanted the Philippines to either fund the clinical trial of their COVID-19 vaccine in the country or recognize China’s approval and authorization of the coronavirus cure, the Department of Science and Technology said Friday......»»
AstraZeneca, Janssen, Clover Pharmaceuticals secure ethics review approval
Health Secretary Maria Rosario Vergeire on Monday said three vaccine firms for COVID-19 have already secured approval from the ethics review board — an essential requirement to be pursued before a clinical trial in the country is allowed. These were British firm AstraZeneca, Janssen by Johnson & Johnson, as well as Clover Pharmaceuticals from China. […] The post AstraZeneca, Janssen, Clover Pharmaceuticals secure ethics review approval appeared first on Daily Tribune......»»
China firm hurdles review panel on vaccine trial
Chinese drugmaker Clover Biopharmaceuticals may soon conduct clinical trials for its COVID-19 vaccine in the country after it secured clearances from both the technical panel of vaccine experts and the ethics review board, Science Secretary Fortunato de la Peña said......»»
Pinakabagong ulat sa pagbuo ng bakuna
Binibigyan ko ng labis na kahalagahan ang mga kaunlaran sa pagbuo ng bakuna laban sa COVID-19 kaya inimbitahan ko sa aking press briefings ang ating mga ambassadors mula sa Estados Unidos, United Kingdom, Russia, at China. Pinagusapan namin ang mga bagong inpormasyon tungkol sa pagpapaunlad ng bakuna sa bansa kung saan sila nakatalaga. The post Pinakabagong ulat sa pagbuo ng bakuna first appeared on Abante......»»
DOST: Trials for China s Sinovac, Clover may start end-2020 or early 2021
The COVID-19 vaccine candidates of Sinovac Biotech Ltd. and Clover Biopharmaceuticals have passed the technical review of the vaccine expert panel for their application to conduct Phase 3 clinical trials in the Philippines......»»
AstraZeneca susubukan bakuna kontra COVID-19 sa ‘Pinas
Nagsumite na ang British pharmaceutical company na AstraZeneca ng mga kinakailangang dokumento upang makapagsagawa ng mga clinical trial ng kanilang bakuna laban sa COVID-19 sa Pilipinas. The post AstraZeneca susubukan bakuna kontra COVID-19 sa ‘Pinas first appeared on Abante......»»